Amneal (AMRX) Q3 2026 Earnings Call Transcript

Amneal reported Q3 2026 revenue of $862.7 million, up 10% year over year, adjusted EBITDA of $207 million, up 30%, and adjusted diluted EPS of $0.26, up 53%. It raised full-year revenue guidance to $3.15 billion-$3.25 billion, adjusted EBITDA guidance to $800 million-$815 million, and EPS guidance to $1.04-$1.08, while lowering operating cash flow guidance to $325 million-$375 million due to inventory investment and collection timing. Affordable Medicines revenue rose 19% and Specialty revenue rose 20%; AvKARE revenue fell 17%, which management attributed to a prior-year product introduction and a focus on profitability. The Kashiv acquisition contributed to net leverage of 3.0x adjusted EBITDA, while management cited biosimilar, specialty, and complex-generic products as growth drivers.

Analysis

The key underwriting question is whether higher adjusted earnings convert to cash: management lowered operating-cash-flow guidance while building inventory and citing collections pushed into Q1 2027. Separately, a $40 million biosimilar order benefited Q3 from timing. Together, these make reported growth less clean than the EBITDA/EPS acceleration suggests; Q4 and Q1 receivables, inventory turns, and repeat-order data should determine whether this is temporary working capital or demand pulled forward. The claimed cash-collection timing is management’s explanation, not yet verified by conversion.

AMRX’s upside case is increasingly a mix-shift thesis, not just a launch-count story: management says biosimilars drive the largest portion of its 2030 growth plan, while Kashiv integration, manufacturing scale-up, and commercial execution are still unproven. Better economics from retaining product profits could lift margins, but acquisition leverage and capex leave less room for launch delays or quality disruptions. The India flooding incident is resolved; it nevertheless highlights concentration and supply-continuity risk in a business selling reliability.

Near term, raised EBITDA/EPS guidance and specialty uptake support sentiment, but some growth includes launch contributions and order timing. Over 1–3 months, watch lanreotide reorder quality, inventory build versus sales, and cash conversion. Over 6–18 months, biosimilar launches and regulatory/patent timing—not the 2030 target—are the valuation catalysts. XOLAIR competition, including Teva, may constrain eventual economics; AMRX’s expected late-2027 launch is not a near-term earnings driver. Pfizer’s GLP-1 manufacturing opportunity is long-dated, with economics and commercial terms not yet specified. Consensus may underweight cash and execution risk, even as it may underappreciate the potential margin benefit of a successful biosimilar mix shift.

Key Decisions for Investors

• AMRX: Consider a staged, modest long rather than chasing the initial earnings reaction; add only if Q4 results show inventory supporting sell-through and collections recover. No valuation or current price data were provided to set an entry level.
• AMRX: Treat the 2026 earnings raise as more credible than the cash-flow outlook until verified. Reassess after Q4/Q1 cash conversion, inventory turns, and repeat biosimilar orders; thesis weakens if receivables remain elevated or inventory grows faster than sales.
• AMRX: Track lanreotide uptake and the 60/90 mg filing and launch schedule, plus biosimilar regulatory and patent milestones. Failure to sustain orders or meaningful launch delays would challenge the growth-and-mix thesis; do not underwrite 2030 targets as near-term catalysts.
• Relative value: Avoid a simple AMRX-versus-TEVA pair based solely on XOLAIR—the launch timing is distant and competitive economics are undisclosed. Revisit when patent settlement, launch timing, and market-access evidence become clearer.